|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.67 USD | -0.03% |
|
+0.40% | +8.74% |
| 05-16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
| 04-30 | Axonics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Axonics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 91.41 million compared to USD 70.65 million a year ago. Net loss was USD 19.11 million compared to USD 9.25 million a year ago.
Basic loss per share from continuing operations was USD 0.38 compared to USD 0.19 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.74% | 3.45B | |
| +11.57% | 127B | |
| -4.96% | 11.32B | |
| +3.22% | 9.04B | |
| +38.90% | 5.56B | |
| -21.83% | 4.72B | |
| -6.82% | 2.86B | |
| -13.32% | 2.04B | |
| -6.99% | 2.07B | |
| -23.90% | 1.77B |
AXONICS, INC. 
